THU0464 PHASE 2 CLINICAL TRIAL OF THE GI SAFETY OF A HYDROGEN SULFIDE-RELEASING ANTI-INFLAMMATORY DRUG (ATB-346)

Published: Jun 1, 2019
Abstract
Background: null Hydrogen sulfide (H2S) is a naturally occurring gaseous mediator produced by intestinal bacteria and various eukaryotic cells. H2S exerts anti-inflammatory, pro-resolution and cytoprotective effects in vivo. ATB-346 is an H2S-releasing derivative of naproxen, which in animals was shown to produce negligible gastrointestinal (GI) damage and bleeding. In human studies, ATB-346 was found to be much more potent and long-lasting than...
Paper Details
Title
THU0464 PHASE 2 CLINICAL TRIAL OF THE GI SAFETY OF A HYDROGEN SULFIDE-RELEASING ANTI-INFLAMMATORY DRUG (ATB-346)
Published Date
Jun 1, 2019
Journal
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.